Uvaria chamae

Uvaria chamae contains bioactive compounds including uvariol, luvangetin, flavonoids, and alkaloids that demonstrate antimalarial properties in laboratory studies. These constituents are believed to interfere with Plasmodium parasite development through multiple pathways, though the precise mechanism requires further investigation. In vitro research shows activity against malaria parasites, but human clinical trials are limited. Evidence Level: C (preliminary research).

Limited research exists on Uvaria chamae drug interactions. Due to its hepatic effects and potential cytochrome P450 enzyme interactions, it may alter the metabolism of certain pharmaceutical drugs. Particular caution is advised when combining with antimalarial medications, as interactions could reduce treatment efficacy. Patients taking prescription medications should consult a healthcare provider before use. Evidence Level: C (theoretical concerns based on constituent properties).

Traditional use suggests 2-4 grams of dried root prepared as a tea for adults, typically consumed once or twice daily for short-term use. Standardized extract dosages have not been established through clinical trials. Duration should be limited, and individuals should consult a qualified healthcare provider for personalized dosing guidance. Evidence Level: Traditional.

Uvaria chamae is considered unsafe during pregnancy and breastfeeding. Traditional knowledge and preliminary research suggest potential uterine stimulant effects and possible risks to fetal development. Women who are pregnant, attempting to conceive, or breastfeeding should avoid this herb entirely. Evidence Level: C (based on traditional use and constituent properties).

Uvaria chamae has been used traditionally in West African medicine for treating malaria, managing pain, and addressing various infections. The root is the primary plant part used, typically prepared as a decoction or tea. It has also been applied for wound healing and as a general antimicrobial agent. Laboratory studies support some antimicrobial and analgesic properties, but human clinical evidence remains limited. Evidence Level: C.

Uvaria chamae may cause mild gastrointestinal effects including nausea, stomach discomfort, and loose stools in some individuals. These effects are typically dose-dependent and may resolve with dosage reduction. Severe adverse effects have not been well-documented, but long-term safety data is lacking. Discontinue use if significant digestive upset occurs and consult a healthcare provider. Evidence Level: C.